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 CURRENTOPINION Pitfalls and novel experimental approaches
to optimize microbial interventions for
chemotherapy-induced gastrointestinal mucositis
Ana R. da Silva Ferreiraa, Hannah R. Wardillb,c, Wim J.E. Tissingb, and
Hermie J.M. Harmsena
Purpose of review
There is a growing number of studies implicating gut dysbiosis in mucositis development. However, few
studies have shed light on the causal relationship limiting translational potential. Here, we detail the key
supportive evidence for microbial involvement, candidate mechanisms by which the microbiome may
contribute to mucositis and emerging approaches to model host–microbe interactions with clinical
relevance and translational potential.
Recent findings
Synthesis of existing clinical data demonstrate that modulating the microbiome drastically alters the
development and severity of mucositis, providing a strong rationale for its involvement. Review of the
literature revealed potential microbiome-dependent mechanisms of mucosal injury including altered drug
metabolism, bile acid synthesis and regulation of the intestinal barrier. Current studies are limited in their
mechanistic insight due to cross-sectional and would benefit from longitudinal analyses and baseline
phenotyping.
Summary
The causative role of the microbiome in mucositis development remains unclear. Future studies must adopt
comprehensive microbial analyses with functional assessment, and utilize emerging ex-vivo models to
interrogate host–microbe interactions in mucositis.
Keywords
chemotherapy-induced gut toxicity, microbiome, microbiota, mucositis, probiotics, the human
oxygen-bacteria anaerobic
INTRODUCTION
Cytotoxic chemo-radiation is notoriously nonselec-
tively, resulting in off-target toxicity to a range of
mucosal surfaces, clinically termed mucositis [1].
The alimentary tract, mouth to anus, is highly sus-
ceptible to mucositis due to its high proliferative
turnover, strong immunological properties and
intestinal excretion of some chemotherapeutic
drugs [2]. While affecting the oral and gastrointesti-
nal tract (GIT) to a comparable degree, oral muco-
sitis has been studied in greater detail reflecting the
ease at which the oral cavity can be assessed com-
pared with the GIT, and the hesitancy of many
patients to discuss gastrointestinal symptoms. This
has resulted in significant under reporting of gastro-
intestinal mucositis (GI-M) and a subsequent dearth
of GI-M focused research.
GI-M is a ubiquitous complication of anticancer
therapy, with pelvic radiotherapy and high-dose
chemotherapy associated with exceptionally high
incidence rates. Clinically, GI-M manifests as diar-
rhea with associated abdominal pain and rectal
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bleeding, requiring intensive supportive care and
impacting patient quality of life. Mucosal barrier
breakdown, including direct apoptosis and tight
junction disruption, are through to drive diarrhea
by impairing luminal absorption and leak-flux
mechanisms [3]. Furthermore, these changes are
considered critical initiating factors in the develop-
ment of lethal secondary complications including
blood stream infection and graft-versus-host disease
(GvHD) [4]. Despite this, GI-M continues to be man-
aged with therapeutic loperamide, which serves only
to slow gastrointestinal transit and fails to address key
mechanisms related to GI-M pathobiology [5]. This
highlights the need to carefully characterise the fac-
tors that contribute to mucosal barrier injury to
identify novel methods of intervention.
A growing body of research now supports the
role of host–microbe interactions in the develop-
ment of GI-M [6]. The development in DNA tech-
nology has showed that chemotherapeutic agents
detrimentally affect the composition of the micro-
biome, either directly or indirectly, with losses in
overall microbial diversity and a compositional shift
toward a Gram-negative dominated pathogenic
enterotype [7,8]. Most importantly, it has been sug-
gested that these changes overlap with the develop-
ment of severe GI-M and may therefore be involved
in its symptomology [9]. Even though the scientific
community firmly accepts disruption of the gut
microbiota in GI-M, like many diseases associated
with microbial dysbiosis, unraveling the causal rela-
tionship remains a daunting and hazardous task
that to date has not been achieved. Studies attempt-
ing to dissect causative mechanisms have revealed
some important aspects, however given the highly
heterogenous landscape of GI-M, many remain reli-
ant on cross section study designs and oversimpli-
fied experimental approaches. This hinders efforts
to make significant advances in our fundamental
understanding and impairs the development of
novel microbial interventions.
In this review, we detail the key mechanisms by
which the microbiome is likely to causally contrib-
ute to mucositis development, highlighting pitfalls
in current experimental approaches and describing
emerging approaches to model host–microbe inter-
actions with clinical relevance and translational
potential in the provision of supportive care.
MODULATING THE MICROBIOME
CHANGES THE COURSE OF
GASTROINTESTINAL MUCOSITIS
The most robust evidence supporting a causative
role of the microbiome in GI-M development and
symptomology comes from modulating its compo-
sition. An example of this causation is the use of
antibiotics. Antibiotics are well recognized to nega-
tively impact the composition of the microbiome,
decreasing diversity and compositional changes. For
example, broad spectrum antibiotics have been
shown to increase relative abundance of Bacter-
oides, Clostridium cluster XI and Escherichia coli
while decreasing commensal bifidobacteria and
Clostridium cluster XI [10,11]. Antibiotics are
largely attributed to poorer treatment outcomes in
a variety of clinical scenarios relating to mucosal
injury. For example, broad spectrum antibiotics
increase the incidence and mortality of GvHD. This
is hypothesised to occur via aggravation of acute
mucosal injury, a key initiating factor of GvHD [12].
This is supported by preclinical data from our labo-
ratory in which antibiotic-induced dysbiosis
increased mucosal injury, impaired recovery and
increased mortality [13]. This evidence also reiter-
ates the long-standing belief that previous mucosal
injury (from previous cycles of chemotherapy) pre-
disposes to GI-M development, a phenomenon that
may be driven by residual deficiencies in the micro-
biome.
It is important to note that these findings differ to
those in which gut deleting protocols or germ-free
mice are used. In these cases, the absolute absence of
the gut microbiota results in protection, highlighting
the importance of a stableand diverse microbiome. In
a study performed by Pedroso et al., the differences in
the phenotypes between germ-free and conventional
mice in the development of irinotecan treatment
KEY POINTS
 It has been shown that gastrointestinal mucositis (GI-M)
drastically alters the composition of the gut microbiota
with these changes overlapping with the development
of severe GI-M.
 Studies attempting to dissect causative mechanisms
have revealed some important aspects, however given
the highly heterogenous landscape of GI-M, many
remain reliant on cross section study designs and
oversimplified experimental approaches.
 Candidate mechanisms for host microbe involvement
include microbial impact on drug metabolism, bile acid
synthesis and barrier function.
 Clinical phenomena should be deeply interrogated
using sophisticated ex-vivo models to
determine causation.
 Organoids, gut-on-a-chip and the human oxygen-
bacteria anaerobic models provide an excellent
alternative to study host–microbe interactions.
Gastrointestinal symptoms
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were studied. Results showed that germ-free mice
presence a resistance in the development of intestinal
damage due after irinotecan administration [14].
Surprisingly, conventionalization of germ-free mice
reversed the resistance phenotype previously
observed in this model. The authors also confirmed
the role of b-glucuronidase bacteria in the induction
of mucositis. In fact, it was observed that the mono-
association of germ-free with b-glucuronidase-
producing bacteria increased permeability after
irinotecan treatment [14].
Similarly, modulating the microbiome with pre
and probiotics has been linked with less GI-M,
although the results are conflicting and variable.
The prebiotics fructose polysaccharide, inulin and
short-chain fructo-oligosaccharide are commonly
investigated in gastrointestinal disorders, largely
inflammatory bowel disease, due to their ability to
increase the amount of bifidobacteria, Roseburia,
Ruminococcaceae and Eubacterium [15,16]. Despite
emerging benefits in other benign inflammatory
conditions of the gut, these have not been investi-
gated in mucositis. However, the prebiotic proper-
ties of vitamins has been investigated, with ascorbic
acid (vitamin C) recently shown to improve out-
comes in a preclinical model of 5-fluorouracil (5-FU)
mucositis [17]. Similarly, administration of the pro-
biotic Bifidobacterium infantis in rats has resulted in
higher body weight and villus height, reduced
expression of Nuclear Factor- kappa B and increased
production of IL-10 and reduced diarrhea in 5-FU-
induced mucositis rats [18,19]. Commercialized pro-
biotics such as VSL#3 have also shown prophylactic
efficacy in reducing diarrhea following irinotecan
administration [20]. Clinically, the efficacy of pro-
biotics has also been demonstrated with several
studies showing independent benefits of certain
stains in mucositis/diarrhea prevention prompting
the 2014 Multinational Association of Supportive
Care in Cancer/International Society of Oral Oncol-
ogy guideline [5,21,22].
Although studies demonstrate benefits particu-
larly in the oncological setting, there remains no
wide-reaching recommendation for probiotics in
the prevention of GI-M. This likely reflects the het-




studies show that modulating the composition of
the gut microbiota can drastically alter the course of
GI-M. Moreover, it also suggests that distinct base-
line gut microbiota enterotypes may be associated
with different toxicity responses. For example, peo-
ple that go on to develop severe symptoms have a
unique and identifiable microbial phenotypes at
baseline that differ to those that do not develop
those symptoms [24–26]. Taken together, these
findings imply that baseline microbiome composi-
tion is critical in shaping toxicity outcomes, thus





Preclinical and clinical studies now demonstrate a
link between the composition of the gut microbiota
and GI-M development [8,9,20,27–29,30
&&
]. Whilst
these findings have undoubtedly shed new light
into the pathogenesis of mucositis, our current
understanding of the causative role that the micro-
biome plays in symptom development remains
unclear. Fundamentally, the microbiome has the
ability to modulate various aspects of mucositis
pathogenesis via its intimate and bidirectional com-
munication with the mucosal immune system, as
elegantly described by Secombe et al. [30
&&
]. How-
ever, there remain several other candidate mecha-
nisms by which the microbiome is likely to
contribute to GI-M, namely via its impact on drug
metabolism, mucosal barrier function and bile
acid synthesis.
Drug metabolism
The most robust evidence mechanistically linking
the microbiome to mucositis is its influence on
chemotherapy drug metabolism. Irinotecan (CPT-
11) is a prodrug that is converted by carboxylesterase
enzymes to SN-38, a potent topoisomerase I inhibi-
tor that is over 1000-fold more toxic than its prodrug
predecessor. Metabolically, SN-38 is conjugated in
the liver to SN-38 glucuronide (SN-38G), its inactive
metabolite that is secreted into the gastrointestinal
tract via bile for eventual excretion [31,32]. How-
ever, as SN-38G passes through the GIT, it acts as
substrate for bacterial b-glucuronidases resulting in
deconjungation of SN-38G to its active metabolite.
This results in direct and extreme exposure of the
gastrointestinal mucosa to SN-38 resulting in pro-
found mucosal injury and the development of CPT-
11-induced diarrhea [33]. In addition to the direct
cytotoxic damage caused by SN-38, this active
metabolite also acts as a ligand for the Toll-like
receptor four (TLR4) coreceptor, MD2, resulting in
TLR4-dependent immune activation and the initia-
tion of an intense inflammatory response. Again,
this is nicely demonstrated by Pedroso et al. [14],
with germ-free mice protected from irinotecan-
induced mucositis compared with wild-type.
Authors concluded that this was due to germ-free
animals being unable to reactive SN-38G, thus
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eliminating its direct toxic effects in the intestinal
lumen.
Comparable evidence also exists detailing the
metabolic impact of the microbiome on other che-
motherapy drugs. In a study performed by Lehour-
itis et al., the effects of E. coli and Listeria welshimeri
on the efficacy of a set of chemotherapeutic drugs
were tested. Authors concluded that the cytotoxicity
of cladribine, vidarabine and gemcitabine were
decreased by bacteria. These alterations were most
probably via enzymatic modifications which dem-
onstrated the interaction between internal bacteria
and drug therapy [34].
Barrier function
A simple mechanism used for antimicrobial protec-
tion is the presence of a two-tiered mucus layer
which maintains the integrity of the intestinal
microbiota and contributes to overall barrier func-
tion [35,36]. Mucins have been shown to have sev-
eral beneficial properties including protection
against bacterial translocation and might also serve
as sources of carbohydrates and peptides [35,36],
and are widely disrupted following chemotherapy
[37,38
&
]. Using a gnotobiotic model in which ani-
mals were colonized with a synthetic human gut
microbiota composed by commensal bacteria, Desai
et al., investigated the link between the gut micro-
biota and colonic mucus barrier. Results show that,
in cases of dysbiosis, a deficiency in nutrients leads
to an increase in the population of mucin-depredat-
ing bacteria. These bacteria will in turn use mucin as
a nutrient which results in barrier disruption. These
results clearly demonstrate the crucial role of the
gut microbiota on mucus integrity, and as such
microbe-dependent mucin degradation is a clear
candidate mechanism by which the microbiome
causally contributes to mucositis [39].
In addition to the apical mucus layer, mucosal
barrier integrity is maintained by intercellular
junction complexes, in particular tight junctions.
Tight junctions are highly dynamic structures, able
to undergo rapid and reversible changes in
response to a variety of physiological and patho-
logical cues [40]. Changes in the molecular integ-
rity and functional capacity of tight junctions is
well described in the setting of GI-M, with both
and clinical evidence demonstrating cytoplasmic
translocation and downregulation of key tight
junction proteins including claudin-1, occludin
and zonular occludens-1 [41,42]. In a study by
Feng et al., antibiotic-treated mice showed severe
alterations in the composition of the gut micro-
biota with paralleled changes in barrier integrity.
Particularly, authors suggest that variations in
Firmicutes and Bacteroides are responsible for
the destruction of the intestinal barrier [43].
Bile acid metabolism
Bile acids are a family of steroid acids synthesized
from cholesterol in the liver and secreted in the
lumen of the intestine [44]. Intestinal microbes such
as Bacteroides intestinalis, Bacteroides fragilis and E.
coli have the necessary enzymes to convert bile acids
into deoxycholic and lithotomic acid in the human
colon [36,44]. When the composition of the micro-
biome is compromised, the ratio of primary/second-
ary bile acids is increased. A study by Fang et al. [45],
suggests that CPT-11-induced metabolic disorders
of bile acids potentially supress the production of
IL-10, which in turns aggravates mucosal barrier
hyper-permeability [45]. In-line with these anec-
dotal observations and mechanistic hypotheses, bile
acid sequestrant colesevelam was shown to reduce
diarrhea in a model of neratinib-induced GI-M [46].
Significantly, diarrhea induced by neratinib was
unrelated to serum neratinib levels suggesting that
modulation of secondary inflammatory processes
(by bile acid modulation) may be more important
in determining the clinical impact of toxicity than
the effects of direct cytotoxicity.
FUTURE DIRECTIONS FOR EXPLOITING
HOST–MICROBE INTERACTIONS IN
MUCOSITIS
Despite anecdotal evidence supporting the role for
the microbiome in mucositis development, it
remains a significant challenge to identify causative
and targetable mechanisms. Clinically, the hetero-
geneity in oncology cohorts, confounding variables
and paralleled antibiotic use are significant
obstacles. In-vitro models often lack the level of
sophistication required to model the intimate and
bidirectional pathways that join the host, immune
system and microbes. As such, sensibly designed
cohort studies which are integrated with novel ex-
vivo platforms are critical to advance our under-
standing of the microbiome in GI-M.
Without an appreciation for the exact microbial
signatures associated with GI-M, it is a difficult task
to manipulate the microbiome in such a way that
induces clinically relevant results. As such, we rec-
ommend that studies focus on comprehensively and
longitudinally characterizing the microbiome,
across various forms of cancer therapy (Fig. 1). This
can be achievable by the implementation of bio-
banks for the high-frequency collection of stool
samples before and during therapy. This will enable
the identification of unique microbial factors that
Gastrointestinal symptoms
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FIGURE 1. Schematic outlining mechanistic contribution of dysbiosis on pathobiology of mucositis. In a state of homeostasis,
commensal bacteria are responsible for several functions, including maintenance of tight junctions and intestinal barrier
function, promoting immune tolerance and stimulating mucus production, which ultimately prevent potentially harmful
organisms from damaging the mucosa. Binding of commensal bacteria to Toll-like receptor’s present on epithelial cells results
in suppression of the Nuclear factor-kappa B pathway and consequent inhibition of proinflammatory production. Gut
homeostasis can be disturbed by chemotherapeutic drugs such as irinotecan, methotrexate and 5-FU. Lipopolysaccharide
produced by Gram-negative bacteria such as Escherichia coli activate the NF-kB pathway, resulting in exacerbated
inflammation and consequently apoptosis. Reduced permeability also allows the entrance of pathogenic bacteria which
aggravate the inflammatory state in the gut. Dysbiosis resulting in increased proteobacteria is also associated with increased
b-glucuronidase production, which serves to amplify irinotecan reactivation and disrupt mucus production. Characterizing the
dynamic shifts in the microbiota relative to baseline is critical in identifying appropriate microbial targets for therapeutic
intervention design. These should be underpinned by novel ex-vivo models to dissect causative mechanisms.
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may be critical in shaping an individual response to
treatment as well as the dynamic changes that occur
throughout mucositis development. Bio banking
efforts must be paired with the comprehensive col-
lection of outcome measures, including objective
biomarkers of GI-M, clinician reported outcomes
and patient reported outcomes [47]. Unique
response phenotypes can then be interrogated in
an ex-vivo manner to understand the microbial
contribution to GI-M development, thus allowing
cause and effect to be dissected.
Although financially burdensome, germ-free
and antibiotic-depleted mice are powerful systems
of preclinical models aimed at dissecting causative
roles [14]. However, these models come with certain
limitations (Table 1). For example, depletion of the
gut microbiota by antibiotics use in animals has
revealed to be challenging due to inability to control
the exact composition and number of organisms
that remain in the gut, with expansion of antibi-
otic-resistant microbes a significant problem. Germ-
free mice also pose significant limitations largely
related to their lack of oral tolerance and hypersen-
sitivity to microbial products [48]. Despite these
limitations, gnotobiotic mice, which are germ-free
mice colonized with selected known populations of
bacteria, have shown success in the field of
Inflammatory Bowel Disease and oncology, with
particular success in understanding individual
response to immunotherapies [49,50].
Alternative ex-vivo models have also been devel-
oped to better study host–microbe interactions. The
human oxygen-Bacteria anaerobic coculturing sys-
tem, developed in our lab by Sadabad et al., is a novel
approach that allows researchers to analyze cell
growth, transcriptome and exo-metabolome of
cocultured cells. This approach allows the study
of host–microbiome interactions, particularly the
investigation of anaerobic bacteria in the gut under
oxidative stress conditions [51]. Other innovating
systems such as gut-on-a-chip and three-dimen-
sional organoid models have gained relevance in
the field of the gut microbiome [52–54]. The gut-on-
a-chip device for instance provides a controlled
study of host–microbial interactions with all the
dynamic physical and functional features of the
human intestine [52]. Organoids have been success-
fully generated from different regions of the GIT.
Although challenging to culture, they offer several
advantages including the ability to propagate for a
long time and the possibility to culture both tissue
and microbes from an individual patient, and eval-
uate their unique response(s). The use of organoids
colonized with microbes, and cocultured with
Table 1. Summary of the advantages/disadvantages of the different approaches to understand the contribution of the
microbiome in gastrointestinal mucositis
Approach Advantage Disadvantage References
Antibiotic-depleted
mice
Low costs of maintenance
Applicability to any genotype
No specialized equipment is necessary
Difficult to control the number and
composition of the gut microbiota
Promotion of fungal outgrowth due to




Bacteria free in all tissues
Exclusive colonization with defined microbes
Maintenance costs




Gut-on-a-chip Controlled study of host–microbial
interactions
All the dynamic physical and functional
features of the human intestine
Ability to integrate different sensors
Absence of an immune system
Costs of maintenance
[55]
3D-organoids 3D architecture of the tissue culture
Possibility to study different diseases
Ability to propagate for a long time
Challenging to culture
Absence of an immune system
[56,57]
Prebiotics Stimulation of mucosal and immune
responses
Demonstrated to increase the amount of
bifidobacteia, Roseburia,
Ruminococcaceae and Eubacterium
Not assessed in the setting of GI-M
Not all prebiotics have resulted in clinical
improvements
[15,16]
Probiotics Promotion of mucus production
Modulation of epithelial barrier function
Activation of immune responses
Inconsistent results
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immune cells would also enable more robust inter-
rogation of host–microbe interactions and their
relevance to mucosal inflammation (Table 1).
It is becoming increasingly evident that an indi-
vidual’s unique pretreatment microbiome may be
critical in determining their response to treatment,
both in terms of its efficacy and toxicity [24,59
&
].
This hypothesis is supported by a growing body of
research in which distinct differences are observed
in the pretreatment microbiome of people that go
on to develop severe mucositis compared with those
that do not. For example, Esfahani et al. [60] dem-
onstrated distinct olfactory signatures, detected
using an e-nose, of pretreatment stool samples in
patients receiving pelvic radiotherapy. Similar
results have been shown in patients with malignant
melanoma treated with Programmed cell death-1
checkpoint inhibitors in which the presence of bifi-
dobacteria and Clostridiales enabled a more efficient
response to PD-1 blockade. These results highlight
the importance of the pretreatment microbiome in
driving treatment response, and thus demonstrate
its potential in risk-prediction strategies, as well as
risk mitigation approaches.
Regardless their limitations, these innovative
systems could provide us with crucial information
on host–microbe interactions. Unraveling this
interactions will help us to dissect the causation
mechanisms therefore guiding us to novel
approaches to prevent GI-M (Fig. 1).
CONCLUSION
Several studies have been reporting the crucial role
of the gut microbiota in the development of muco-
sitis [9,35]. Indeed, both preclinical and clinical
studies show that anticancer treatment is associated
with a decrease in microbial diversity and a decrease
in the number of anaerobic bacteria [9,35]. Further-
more, this decrease usually coincided with the
development of severe mucositis. We now need
to adequately characterise the microbial popula-
tions unique to different chemotherapeutic agents,
to design and develop the ideal microbiota protec-
tant (Fig. 1). Once the most favorable microbiota
composition for each clinical condition has been
identified, the next challenge will be how to modify
the patient’s microbiota. The resilience and stabil-
ity of the gut microbiota and its responsiveness to
physiological, pathological and environmental
changes are characteristics that would enable us
to use the microbiota composition as a biomarker,
a diagnostic tool and possibly a therapeutic target.
However, we believe that a preinterventional char-
acterization of the gut microbiota will help us
to develop sophisticated approaches to reduce
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